Effects of oxytocin on methamphetamine-induced conditioned place preference and the possible role of glutamatergic neurotransmission in the medial prefrontal cortex of mice in reinstatement.
Accumulating evidence has shown the neuroactive properties of oxytocin (OT), a neurohypophyseal neuropeptide, and its ability to reduce the abuse potential of drugs. The present study investigated the effects of OT on the conditioned place preference (CPP) induced by methamphetamine (MAP, 2.0 mg/kg, i.p.) in mice and the possible role of glutamatergic neurotransmission in the reinstatement of CPP. The results showed that OT (0.1, 0.5, 2.5 microg, i.c.v.) significantly inhibited the acquisition and facilitated the extinction of MAP-induced CPP and abolished the reinstatement of CPP induced by restraint stress. This effect of OT could be attenuated by atosiban (Ato, 2.0 microg, i.c.v.), a selective OT-receptor antagonist. OT failed to block the expression and the reinstatement of CPP induced by MAP challenge. Extracellular glutamate (Glu) levels in the medial prefrontal cortex (mPFC) were determined using microdialysis coupled to a high-performance liquid chromatography (HPLC) with a fluorescence detection system. The results indicated that OT markedly inhibited extracellular Glu levels induced by restraint stress in CPP mice, but not those induced by MAP priming. Ato also attenuated the effects of OT on the changes in Glu levels. Therefore, these findings suggest that OT inhibits drug reward-related behaviors induced by MAP via the OT receptor, and OT blocks the reinstatement of CPP, at least partially, by interfering with the glutamatergic system in the mPFC.
Department of Pharmacology, Life Science and Biopharmaceutics School, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jia
J
Qi
Jing-Yu
JY
Yang
Fang
F
Wang
Ya-Nan
YN
Zhao
Ming
M
Song
Chun-Fu
CF
Wu
D019969:Amphetamine-Related Disorders / Q000503:physiopathology* / Q000523:psychology; D000818:Animals; D003213:Conditioning, Psychological / Q000187:drug effects*; D018698:Glutamic Acid / Q000502:physiology*; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology*; D051379:Mice; D017551:Microdialysis; D009043:Motor Activity / Q000187:drug effects*; D009294:Narcotics / Q000494:pharmacology*; D018377:Neurotransmitter Agents / Q000502:physiology*; D010121:Oxytocin / Q000494:pharmacology*; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000378:metabolism; D012149:Restraint, Physical; D012201:Reward; D013315:Stress, Psychological / Q000378:metabolism / Q000503:physiopathology
D009294:Narcotics; D018377:Neurotransmitter Agents; D018698:Glutamic Acid; D008694:Methamphetamine; D010121:Oxytocin